NeRRe Therapeutics

OverviewSuggest Edit

NeRRe Therapeutics is a clinical-stage company developing a pipeline of three neurokinin-1 antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity associated with neurokinin-1 receptor system dysfunction.

TypePrivate
Founded2012
HQStevenage, GB
Websitenerretherapeutics.com

Latest Updates

Employees (est.) (Jan 2022)11
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at NeRRe Therapeutics

Andrew Kay

Andrew Kay

Chairman
Mary Kerr

Mary Kerr

Chief Executive Officer, Board Member
Kaasim Mahmood

Kaasim Mahmood

Board Member
Ena Prosser

Ena Prosser

Board Member
Geert-Jan Mulder

Geert-Jan Mulder

Board Member
Javier García

Javier García

Founder, Columbus Venture Partners
Show more

NeRRe Therapeutics Office Locations

NeRRe Therapeutics has offices in Stevenage and Hertfordshire
Stevenage, GB (HQ)
Gunnels Wood Rd
Hertfordshire, GB
Catalyst Incubator Building Gunnels Wood Rd
Show all (2)

NeRRe Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2012

NeRRe Therapeutics total Funding

$49.2 m

NeRRe Therapeutics latest funding size

$30.77 m

Time since last funding

5 years ago

NeRRe Therapeutics investors

NeRRe Therapeutics's latest funding round in January 2017 was reported to be $30.8 m. In total, NeRRe Therapeutics has raised $49.2 m
Show all financial metrics

NeRRe Therapeutics Revenue

Cash (30-Jun-2018)

8.0m
GBPFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.4m1.9m2.7m4.0m8.0m

Accounts Receivable

322.7k

Current Assets

1.7m2.2m3.0m5.7m10.3m
FY, 2014

Financial Leverage

3.5 x
Show all financial metrics

NeRRe Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

NeRRe Therapeutics Online and Social Media Presence

Embed Graph

NeRRe Therapeutics News and Updates

NeRRe Therapeutics raises £20 million in a Series B2 financing round

NeRRe Therapeutics raises £20 million in a Series B2 financing round

NeRRe Therapeutics Blogs

Steve Pawsey, Chief Medical Officer at NeRRe Therapeutics is presenting at The Eleventh International Virtual Cough Symposium, 21-22 January 2021, London, UK

Steve Pawsey, Chief Medical Officer at NeRRe Therapeutics is presenting at The Eleventh International Virtual Cough Symposium, 21 – 22 January 2021, London, UK The Eleventh International Virtual Cough Symposium

Dr Mary Kerr, CEO of NeRRe Therapeutics to present at Biotech Showcase virtual event 11-15 January 2021

Dr Mary Kerr, CEO of NeRRe Therapeutics to present at Biotech Showcase virtual event 11-15 January 2021 Biotech Showcase

Dr Mary Kerr, CEO of NeRRe Therapeutics to Present at Biotech Showcase in San Francisco on 13 January 2020

Dr Mary Kerr, CEO of NeRRe Therapeutics to present at Biotech Showcase in San Francisco on 13 January 2020, at 2.30PM, Franciscan C (Ballroom Level)
Show more

NeRRe Therapeutics Frequently Asked Questions

  • When was NeRRe Therapeutics founded?

    NeRRe Therapeutics was founded in 2012.

  • Who are NeRRe Therapeutics key executives?

    NeRRe Therapeutics's key executives are Andrew Kay, Mary Kerr and Kaasim Mahmood.

  • How many employees does NeRRe Therapeutics have?

    NeRRe Therapeutics has 11 employees.

  • Who are NeRRe Therapeutics competitors?

    Competitors of NeRRe Therapeutics include Genomatica, Arven Ilac and CELLEX.

  • Where is NeRRe Therapeutics headquarters?

    NeRRe Therapeutics headquarters is located at Gunnels Wood Rd, Stevenage.

  • Where are NeRRe Therapeutics offices?

    NeRRe Therapeutics has offices in Stevenage and Hertfordshire.

  • How many offices does NeRRe Therapeutics have?

    NeRRe Therapeutics has 2 offices.